Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | ALKBH1 | Q13686 | 3/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935977 | 0.88 | PRMT5 (0.61) | KDM4ENPC1RAB9ALMNAPRMT5 | |
| SCHEMBL2155344 | 0.82 | MAPT (0.59) | KDM4ENPC1RAB9ALMNAPRMT5 | |
| SCHEMBL15952657 | 0.81 | KIT (0.54) | NPC1RAB9AGPR119KITSLC6A7 | |
| SCHEMBL26077214 | 0.79 | KIT (0.53) | NPC1RAB9AKITSLC6A7ALKBH1 | |
| SCHEMBL15953346 | 0.79 | KIT (0.53) | NPC1RAB9AKITSLC6A7ALKBH1 | |
| SCHEMBL21551042 | 0.79 | SLC6A7 (0.62) | KDM4EGPR119KITSLC6A7ALKBH1 | |
| SCHEMBL12833327 | 0.79 | KIT (0.54) | KDM4ENPC1RAB9AGPR119KIT | |
| SCHEMBL26077251 | 0.79 | KIT (0.53) | KDM4ELMNAGPR119KITSLC6A7 | |
| SCHEMBL1448399 | 0.78 | GPR119 (0.67) | GPR119KITMMP13 | |
| SCHEMBL28649345 | 0.77 | PRMT5 (0.50) | PRMT5GPR119KITSLC6A7ALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251166-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-109251166-A | The aminated compounds for inhibiting SSAO/VAP-1 and its application in medicine | 广东东阳光药业有限公司 | 2019-01-22 | — | — | CN | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | KDM4E 1414/4885NPC1 406/4885RAB9A 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.